| Page 2 of 2 < |
Experimental MS Vaccine Proves Safe in Early Test
|
TOOLBOX
   Resize
COMMENT
 Discussion Policy
 CLOSE
Comments that include profanity or personal attacks or other inappropriate comments or material will be removed from the site. Additionally, entries that are unsigned or contain "signatures" by someone other than the actual author will be removed. Finally, we will take steps to block users who violate any of our posting standards, terms of use or privacy policies or any other policies governing this site. Please review the full rules governing commentaries and discussions. You are fully responsible for the content that you post.
Who's Blogging  |
The same approach could also be used to treat other autoimmune diseases, such as type 1 diabetes, lupus, myasthenia gravis and rheumatoid arthritis, the researchers said.
Patricia O'Looney, vice president of biomedical research programs at the National Multiple Sclerosis Society, thinks this new approach is promising, but the concept still needs to be proven in larger trials.
"This is like science fiction. It's something that wouldn't have even been thought about 10 years ago," O'Looney said.
Still, the results offer hope, she said.
"This is a fascinating approach to try to control the immune activity with folks with MS," she said. "We are always looking for new ways to help people with MS. It is important that this is a novel idea, and we will just have to watch and see if it goes forward."
More information
For more on multiple sclerosis, visit the National Multiple Sclerosis Society.
SOURCES: Amit Bar-Or, M.D., Montreal Neurological Institute of McGill University, Canada; Patricia O'Looney, Ph.D., vice president, biomedical research programs, National Multiple Sclerosis Society, New York City; Aug. 13, 2007,Archives of Neurology, online
![[slate.com logo]](http://media.washingtonpost.com/wp-dyn/content/graphic/2007/09/27/GR2007092701096.GIF)
